Cargando…

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders

Most research on fluid biomarkers for central nervous system (CNS) disorders has so far been performed using cerebrospinal fluid (CSF) as the biomarker source. CSF has the advantage of being closer to the brain than serum or plasma with a relative enrichment of CNS-specific proteins that are present...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andreasson, Ulf, Blennow, Kaj, Zetterberg, Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Blood Based Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941042/ https://www.ncbi.nlm.nih.gov/pubmed/27453931 http://dx.doi.org/10.1016/j.dadm.2016.05.005

Ejemplares similares

Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
por: Wang, Pei‐Ning, et al.
Publicado: (2020)

Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre‐analytical conditions
por: Simrén, Joel, et al.
Publicado: (2021)

Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Crosswalk study on blood collection‐tube types for Alzheimer's disease biomarkers
por: Jonaitis, Erin M., et al.
Publicado: (2022)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

Elevated plasma neurofilament light in aging reflects brain white‐matter alterations but does not predict cognitive decline or Alzheimer's disease
por: Nyberg, Lars, et al.
Publicado: (2020)

Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles
por: Keshavan, Ashvini, et al.
Publicado: (2018)

Association between serum urate and CSF markers of Alzheimer's disease pathology in a population‐based sample of 70‐year‐olds
por: Fatima, Tahzeeb, et al.
Publicado: (2021)

The global Alzheimer's Association round robin study on plasma amyloid β methods
por: Pannee, Josef, et al.
Publicado: (2021)

Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges
por: O'Bryant, Sid E., et al.
Publicado: (2015)

Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline
por: Uchida, Kazuhiko, et al.
Publicado: (2015)

Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers
por: DeMarshall, Cassandra A., et al.
Publicado: (2016)

LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project
por: de Leeuw, Francisca A., et al.
Publicado: (2020)

Blood‐based biomarkers for Alzheimer's pathology and the diagnostic process for a disease‐modifying treatment: Projecting the impact on the cost and wait times
por: Mattke, Soeren, et al.
Publicado: (2020)

Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort
por: Gupta, Veer Bala, et al.
Publicado: (2017)

Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging
por: Gupta, Veer Bala, et al.
Publicado: (2015)

A blood screening test for Alzheimer's disease
por: O'Bryant, Sid E., et al.
Publicado: (2016)

Blood-based metabolic signatures in Alzheimer's disease
por: de Leeuw, Francisca A., et al.
Publicado: (2017)

Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
por: Thijssen, Elisabeth H., et al.
Publicado: (2022)

Blood protein predictors of brain amyloid for enrichment in clinical trials?
por: Ashton, Nicholas J., et al.
Publicado: (2015)

Differential blood DNA methylation across Lewy body dementias
por: Nasamran, Chanond A., et al.
Publicado: (2021)

Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker
por: Oh, Esther S., et al.
Publicado: (2015)

Alterations of membrane protein expression in red blood cells of Alzheimer's disease patients
por: Várady, György, et al.
Publicado: (2015)

Blood DNA methylation signatures to detect dementia prior to overt clinical symptoms
por: Fransquet, Peter Daniel, et al.
Publicado: (2020)

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
por: Fandos, Noelia, et al.
Publicado: (2017)

Blood-based protein predictors of dementia severity as measured by δ: Replication across biofluids and cohorts
por: Royall, Donald R., et al.
Publicado: (2019)

Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
por: Shen, Xue‐Ning, et al.
Publicado: (2020)

Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile
por: Winston, Charisse N., et al.
Publicado: (2016)

Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia
por: van Wijk, Nick, et al.
Publicado: (2017)

Aβ misfolding in blood plasma measured by immuno‐infrared‐sensor as an age‐independent risk marker of Alzheimer's disease
por: Möllers, Tobias, et al.
Publicado: (2021)

A panel of blood lipids associated with cognitive performance, brain atrophy, and Alzheimer's diagnosis: A longitudinal study of elders without dementia
por: Ma, Ya‐Hui, et al.
Publicado: (2020)

The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis
por: Forgrave, Lauren M., et al.
Publicado: (2019)

Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort
por: Gonzales, Mitzi M., et al.
Publicado: (2022)

Plasma BDNF levels associate with Pittsburgh Compound B binding in the brain
por: Hwang, Kristy S., et al.
Publicado: (2015)

The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment
por: Klavins, Kristaps, et al.
Publicado: (2015)

Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology
por: Savica, Rodolfo, et al.
Publicado: (2016)

Molecular markers of neuropsychological functioning and Alzheimer's disease
por: Edwards, Melissa, et al.
Publicado: (2015)

Reduced plasma desmosterol-to-cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease
por: Sato, Yoshiaki, et al.
Publicado: (2015)

Repeated systemic inflammation was associated with cognitive deficits in older Britons
por: Tampubolon, Gindo
Publicado: (2015)

MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer's disease
por: Guedes, Joana R., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_51dq329mvbpne5lvchjuoi766h